KR100208114B1 - 4-(디-n-프로필)아미노-6-아미노카보닐-1,3,4,5-테트라하이드로벤즈(cd)인돌의 결정형 염 - Google Patents

4-(디-n-프로필)아미노-6-아미노카보닐-1,3,4,5-테트라하이드로벤즈(cd)인돌의 결정형 염 Download PDF

Info

Publication number
KR100208114B1
KR100208114B1 KR1019910003029A KR910003029A KR100208114B1 KR 100208114 B1 KR100208114 B1 KR 100208114B1 KR 1019910003029 A KR1019910003029 A KR 1019910003029A KR 910003029 A KR910003029 A KR 910003029A KR 100208114 B1 KR100208114 B1 KR 100208114B1
Authority
KR
South Korea
Prior art keywords
indole
amino
tetrahydrobenz
aminocarbonyl
propyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019910003029A
Other languages
English (en)
Korean (ko)
Other versions
KR910021375A (ko
Inventor
죠셉 크레스 토마스
리 배리 데이비드
Original Assignee
피터 지. 스트링거
일라이 릴리 앤드 컴퍼니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 피터 지. 스트링거, 일라이 릴리 앤드 컴퍼니 filed Critical 피터 지. 스트링거
Publication of KR910021375A publication Critical patent/KR910021375A/ko
Application granted granted Critical
Publication of KR100208114B1 publication Critical patent/KR100208114B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/80[b, c]- or [b, d]-condensed
    • C07D209/90Benzo [c, d] indoles; Hydrogenated benzo [c, d] indoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1019910003029A 1990-02-26 1991-02-25 4-(디-n-프로필)아미노-6-아미노카보닐-1,3,4,5-테트라하이드로벤즈(cd)인돌의 결정형 염 Expired - Fee Related KR100208114B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48518590A 1990-02-26 1990-02-26
US7/485185 1990-02-26
US07/485185 1990-02-26

Publications (2)

Publication Number Publication Date
KR910021375A KR910021375A (ko) 1991-12-20
KR100208114B1 true KR100208114B1 (ko) 1999-07-15

Family

ID=23927224

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910003029A Expired - Fee Related KR100208114B1 (ko) 1990-02-26 1991-02-25 4-(디-n-프로필)아미노-6-아미노카보닐-1,3,4,5-테트라하이드로벤즈(cd)인돌의 결정형 염

Country Status (28)

Country Link
US (1) US5397799A (enExample)
EP (1) EP0444852B1 (enExample)
JP (1) JP3157007B2 (enExample)
KR (1) KR100208114B1 (enExample)
CN (1) CN1027503C (enExample)
AT (1) ATE126506T1 (enExample)
AU (1) AU629453B2 (enExample)
BR (1) BR9100767A (enExample)
CA (1) CA2037099C (enExample)
CY (1) CY1887A (enExample)
DE (1) DE69112099T2 (enExample)
DK (1) DK0444852T3 (enExample)
ES (1) ES2077796T3 (enExample)
FI (1) FI95464C (enExample)
GR (1) GR3017940T3 (enExample)
HK (1) HK175495A (enExample)
HU (1) HU217118B (enExample)
IE (1) IE67801B1 (enExample)
IL (1) IL97306A (enExample)
LV (1) LV10251B (enExample)
NO (1) NO174149C (enExample)
NZ (1) NZ237181A (enExample)
PT (1) PT96852B (enExample)
RU (2) RU2034837C1 (enExample)
SG (1) SG69975A1 (enExample)
TW (1) TW219933B (enExample)
YU (1) YU47594B (enExample)
ZA (1) ZA911258B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5302612A (en) * 1990-02-26 1994-04-12 Eli Lilly And Company 6-substituted-hexahydrobenz[cd]indoles
IL97309A (en) * 1990-02-26 1996-11-14 Lilly Co Eli Intermediates for hexahydrobenz Úcd¾ indoles and process for the preparation of pure enantiomers thereof
IL97308A (en) * 1990-02-26 1996-10-31 Lilly Co Eli 6-Substituted-hexahydrobenz (cd) indoles process for their preparation and pharmaceutical compositions containing them
US5364856A (en) * 1991-03-28 1994-11-15 Eli Lilly And Company 6-heterocyclic-4-amino-1,3,4,5-tetrahydrobenz[CD]indoles
US5643934A (en) * 1991-03-28 1997-07-01 Eli Lilly And Company 6-heterocyclic-4-amino-1,2,2a,3,4,5-hexahydrobenz [CD]indoles
TW248556B (enExample) * 1993-01-18 1995-06-01 Takeda Pharm Industry Co
UA53205C2 (en) * 2002-04-03 2006-06-15 Pharmatech Close Joint Stock C Antidepressant formulation and method for its manufacture
US7588924B2 (en) 2006-03-07 2009-09-15 Procter & Gamble Company Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
MX2009000286A (es) 2006-06-26 2009-03-20 Procter & Gamble Inhibidores de prolil hidroxilasa y metodos de uso.
MY160066A (en) 2009-11-06 2017-02-15 Aerpio Therapeutics Inc Methods for increasing the stabilization of hypoxia inducible factor-1 alpha
MX2013014310A (es) 2011-06-06 2014-01-23 Akebia Therapeutics Inc Compuestos y composiciones para estabilizar el factor-2 alfa inducible por hipoxia como un metodo para tratar el cancer.
NO2686520T3 (enExample) 2011-06-06 2018-03-17
CN114404414A (zh) 2013-06-13 2022-04-29 阿克比治疗有限公司 用于治疗贫血症的组合物和方法
KR102495018B1 (ko) 2013-11-15 2023-02-06 아케비아 테라퓨틱스 인코포레이티드 {[5-(3-클로로페닐)-3-하이드록시피리딘-2-카보닐]아미노}아세트산의 고체형, 이의 조성물 및 용도
EP3247355A4 (en) 2015-01-23 2018-06-13 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
EA036920B1 (ru) 2015-04-01 2021-01-15 Экебиа Терапьютикс, Инк. Композиции и способы для лечения анемии
TW202406895A (zh) 2018-05-09 2024-02-16 美商阿克比治療有限公司 用於製備2-[[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基]乙酸之方法
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4110339A (en) * 1977-11-25 1978-08-29 Eli Lilly And Company 4-(Di-n-propyl)amino-1,3,4,5-tetrahydrobenz[cd]indole
US4576959A (en) * 1984-02-06 1986-03-18 Eli Lilly And Company 6-Substituted-4-dialkylaminotetrahydrobenz[c,d]indoles
US4745126A (en) * 1987-03-12 1988-05-17 Eli Lilly And Company Method of treating anxiety with tetrahydrobenz[c,d]indole-6-carboxamides
DE3809155A1 (de) * 1988-03-18 1989-09-28 Bayer Ag 1,3,4,5-tetrahydrobenz-(c,d)-indole
US5204340A (en) * 1989-04-11 1993-04-20 Eli Lilly And Company Tetrahydrobenz(c,d)indole serotonin agonists
US5229409A (en) * 1990-08-15 1993-07-20 Eli Lilly And Company 6-substituted-tetrahydrobenz[cd]indoles

Also Published As

Publication number Publication date
LV10251A (lv) 1994-10-20
DE69112099T2 (de) 1996-02-08
EP0444852A3 (en) 1992-02-19
FI910895A0 (fi) 1991-02-25
NO910735L (no) 1991-08-27
NO174149B (no) 1993-12-13
BR9100767A (pt) 1991-10-29
TW219933B (enExample) 1994-02-01
YU47594B (sh) 1995-10-24
NO910735D0 (no) 1991-02-25
FI95464C (fi) 1996-02-12
US5397799A (en) 1995-03-14
GR3017940T3 (en) 1996-02-29
SG69975A1 (en) 2000-01-25
RU2034837C1 (ru) 1995-05-10
DE69112099D1 (de) 1995-09-21
EP0444852B1 (en) 1995-08-16
DK0444852T3 (da) 1995-12-11
ATE126506T1 (de) 1995-09-15
HUT56542A (en) 1991-09-30
RU2083561C1 (ru) 1997-07-10
NZ237181A (en) 1992-06-25
JP3157007B2 (ja) 2001-04-16
FI910895L (fi) 1991-08-27
LV10251B (en) 1995-04-20
IL97306A0 (en) 1992-05-25
ES2077796T3 (es) 1995-12-01
EP0444852A2 (en) 1991-09-04
PT96852A (pt) 1991-10-31
CN1054589A (zh) 1991-09-18
KR910021375A (ko) 1991-12-20
AU7197191A (en) 1991-08-29
AU629453B2 (en) 1992-10-01
NO174149C (no) 1994-03-23
HK175495A (en) 1995-11-24
IE67801B1 (en) 1996-05-01
FI95464B (fi) 1995-10-31
ZA911258B (en) 1992-10-28
CA2037099C (en) 2001-09-11
CY1887A (en) 1996-04-05
JPH04217662A (ja) 1992-08-07
YU32791A (sh) 1994-01-20
PT96852B (pt) 1998-07-31
IL97306A (en) 1996-10-16
HU217118B (hu) 1999-11-29
CN1027503C (zh) 1995-01-25
CA2037099A1 (en) 1991-08-27
IE910625A1 (en) 1991-08-28

Similar Documents

Publication Publication Date Title
KR100208114B1 (ko) 4-(디-n-프로필)아미노-6-아미노카보닐-1,3,4,5-테트라하이드로벤즈(cd)인돌의 결정형 염
DK175400B1 (da) Gabapentin, monohydrat
US12172960B2 (en) Organic compound salts
PT1020464E (pt) Metanossulfonato de paroxetina
US5354760A (en) Crystalline Tiagabine monohydrate, its preparation and use
DE3131752A1 (de) Heterocyclische verbindungen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
CH651040A5 (fr) Procedes de preparation de trans-5-aryl-2,3,4,4a,5,9b-hexahydro-1h-pyrido(4,3-b)-indoles substitues en position 2 dextrogyres et medicament les contenant.
TWI445697B (zh) 塔適那偉(atazanavir)硫酸氫鹽之製法及其新穎的形式
KR100659927B1 (ko) 다형태를갖는독사조신메실레이트의새로운형태(제iii형)
JPH06192228A (ja) 結晶性(r)−(−)−2−シクロヘプチル−n−メチルスルフオニル−[4−(2−キノリニルメトキシ)−フエニル]−アセトアミド
US20060223841A1 (en) Stable pharmaceutical compositions of desloratadine and processes for preparation of polymorphic forms of desloratadine
EP1950204A1 (en) Amorphous form of valsartan
JPH04211079A (ja) cis−3−アミノ−4−[2−(2−フリル)エタン−1−イル]−1−メトキシカルボニルメチル−アゼチジン−2−オンの分割方法
EA011894B1 (ru) Новая псевдополиморфная форма деслоратадина, образованная с диоксидом углерода
JP2004530725A (ja) フェニルエタノールアミンの結晶形、その製造、およびそれを含む医薬組成物
EP0761656B1 (en) Alternate crystal form of tazofelone ((+,-)-5-((3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)methyl)-4-thiazolidinone)
JP3001975B2 (ja) 結晶性チアガビン塩酸塩−水和物、その製造方法および用途
KR20090009898A (ko) 염 및 그의 결정 변체
HK1013822A (en) Alternate crystal form of tazofelone ((+,-)-5-((3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)methyl)-4-thiazolidinone)
JPH02221266A (ja) N,n―ビス―[3―(3,4,5―トリメトキシベンゾイルオキシ)プロピル]ホモピペラジンの製造方法

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

FPAY Annual fee payment

Payment date: 20060331

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20070415

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20070415

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000